Your SlideShare is downloading. ×
0
What You Need To Know About Novartis' Most Important Drugs
What You Need To Know About Novartis' Most Important Drugs
What You Need To Know About Novartis' Most Important Drugs
What You Need To Know About Novartis' Most Important Drugs
What You Need To Know About Novartis' Most Important Drugs
What You Need To Know About Novartis' Most Important Drugs
What You Need To Know About Novartis' Most Important Drugs
What You Need To Know About Novartis' Most Important Drugs
What You Need To Know About Novartis' Most Important Drugs
What You Need To Know About Novartis' Most Important Drugs
What You Need To Know About Novartis' Most Important Drugs
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

What You Need To Know About Novartis' Most Important Drugs

4,023

Published on

Novartis' (NYSE: NVS) is one of the planet's top drug manufacturers and its 3% dividend yield makes it a staple in dividend investor portfolios. …

Novartis' (NYSE: NVS) is one of the planet's top drug manufacturers and its 3% dividend yield makes it a staple in dividend investor portfolios.
However, Novartis' is facing significant threats from competitors Biogen Idec (NASDAQ: BIIB) and Regeneron (NASDAQ: REGN) which could crimp sales even as generic competition heats up for Novartis' multi-billion blockbuster drug Diovan.
In the following slideshow, you'll learn more about Novartis' most important drugs and the threats and opportunities the lie ahead for them.

Published in: Healthcare
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
4,023
On Slideshare
0
From Embeds
0
Number of Embeds
12
Actions
Shares
0
Downloads
18
Comments
0
Likes
2
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. What You Need To Know About Novartis’ Top Selling Drugs
  • 2. Novartis’ Q2 revenue – Second quarter sales totaled $14.6 billion, up 2%. – Emerging markets grew 8%. – Pharmaceuticals sales up 1% to $8.2 billion. – Alcon (eye care) sales up 4% to $2.8 billion. – Sandoz (generics) sales up 4% to $2.3 billion. – Consumer health sales up 5% to $1.05 billion. – Vaccines sales down 14% to $240 million. Novartis’ revenue is growing slowly.
  • 3. Pharmaceuticals = most important • Pharmaceutical product sales account for 56% of Novartis’ sales. • 3 blockbusters are grew more than 20% year-over-year in Q2.
  • 4. Lucentis • Lucentis sales improved 7% to $619 million in Q2. • Novartis’ owns ex-U.S. rights. •Ex-U.S. market opportunity totals $6 billion annually by 2018. •Market share stabilizing in wet- AMD versus Regeneron & Sanofi’s Eylea. •First quarter 2014 Eylea global net sales increased 54% to $577 million. •Emerging markets growing more quickly than developed markets.
  • 5. Gilenya • Gilenya sales improved 28% to $606 million in Q2. •Ex-U.S. No. 1 market share for oral MS treatment. •Biogen’s Tecfidera launches this year and threatens share. •Biogen’s Tecfidera approved in March 2013. •Tecfidera has already displaced Gilenya as the No. 1 oral MS drug in the U.S. with $460 million in Q1 U.S. sales.
  • 6. Afinitor • Afinitor sales improved 25% to $384 million in Q2. •Breast cancer approval helps drive sales growth. •5 potential label expansions by 2017. •HER2 breast cancer: 1st line. •HER2 breast cancer: 2nd/3rd line. •Potential peak sales of $2 billion+.
  • 7. Diovan headwind grows Rough waters for its blockbuster Diovan. •Sales fell 20% YoY in 2013 after losing patent protection. •Sales still totaled $3.5 billion in 2013. •Q2 sales weaker on U.S. inventory de-stocking ahead of generic launch. •Ranbaxy won FDA approval of its generic Diovan in June. •More risk coming.
  • 8. Zometa headwind continues Zometa sales have fallen even more quickly. • Zometa sales down 53% to $600 million in 2013. • Sales fell 53% to $76 million in Q2. • Sales are down 63% to $150 million in 1H2014.
  • 9. Pipeline opportunity • Zykadia won FDA approval in April for ALK+ non-small cell lung cancer. • Small patient population. • 2nd line use behind Pfizer’s Xalkori. • Xalkori sales of $350 million in 2013. • LBH589 filed for FDA approval in Q2 for multiple myeloma. • Outperformed Velcade in phase 3. • LDE225 filed for EU approval in Q2 for advanced basal cell carcinoma.
  • 10. Fool-worthy thoughts •Pharmaceuticals segment headwinds increase this year due to Diovan monotherapy generic launch. •Lucentis’ wet-AMD sales stabilizing; however, Eylea label expansion to DME could threaten sales in 2015. •Tecfidera roll-out globally will eat into Gilenya ex-U.S. sales. •New drug approvals will need to offset considerable headwinds.
  • 11. .Crush non-dividend paying stocks over the long term.

×